<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142758">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01692184</url>
  </required_header>
  <id_info>
    <org_study_id>AVL-292-004</org_study_id>
    <nct_id>NCT01692184</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292</brief_title>
  <official_title>A Phase 1, Two-part Study to Investigate the Safety and Pharmacokinetics of AVL-292 Following Multiple Oral Doses and to Evaluate the Effect of Food on the Pharmacokinetics of Avl-292 Following a Single Oral Dose in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part study.  The first part is to evaluate the safety, pharmacokinetics and
      pharmacodynamics of AVL-292 following multiple oral doses; and the second part is to
      evaluate the effect of food on the pharmacokinetics of a single oral dose of AVL-292.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 28 days after last AVL-292 dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-(Cmax)</measure>
    <time_frame>24 hours after the last AVL-292 dose on days 1 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum observed concentration in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-(AUC)</measure>
    <time_frame>24 hours after the last AVL-292 dose days 1 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration-time curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic response measured in percentage of target occupancy by AVL-292 in peripheral blood mononuclear cells</measure>
    <time_frame>24 hours after the last AVL-292 dose days 1 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacodynamic response measured in percentage of target occupancy by AVL-292 in peripheral blood mononuclear cells</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>50 mg of AVL-292 and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg AVL-292</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg of AVL-292 and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg AVL-292</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg of AVL-292 and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg AVL-292</description>
  </arm_group>
  <arm_group>
    <arm_group_label>350 mg of AVL-292 and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>350 mg AVL-292</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg of AVL-292</intervention_name>
    <description>50 mg AVL-292 (2X 25 mg AVL-292 capsules and 6 placebo capsules) once daily for 7 days administered orally under fasted condition</description>
    <arm_group_label>50 mg of AVL-292 and Placebo</arm_group_label>
    <other_name>AVL-292</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg of AVL-292</intervention_name>
    <description>100 mg AVL-292 (4X 25 mg AVL-292 capsules and 4 placebo capsules) once daily for 7 days administered orally under fasted condition</description>
    <arm_group_label>100 mg of AVL-292 and Placebo</arm_group_label>
    <other_name>AVL-292</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg of AVL-292</intervention_name>
    <description>200 mg AVL-292 (8X 25 mg AVL-292 capsules and 8 placebo capsules) once daily for 7 days administered orally under fasted condition.</description>
    <arm_group_label>200 mg of AVL-292 and Placebo</arm_group_label>
    <other_name>AVL-292</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>350 mg of AVL-292</intervention_name>
    <description>350 mg AVL-292 (14X 25 mg AVL-292 capsules and 14 placebo capsules) once daily for 7 days administered orally under fasted condition</description>
    <arm_group_label>350 mg of AVL-292 and Placebo</arm_group_label>
    <other_name>AVL-292</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>50 mg of AVL-292 and Placebo</arm_group_label>
    <arm_group_label>100 mg of AVL-292 and Placebo</arm_group_label>
    <arm_group_label>200 mg of AVL-292 and Placebo</arm_group_label>
    <arm_group_label>350 mg of AVL-292 and Placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects of any ethnic origin between ages of 18 and 65 with a
             body mass index between 18 and 33

        Exclusion Criteria:

          -  Recent history (i.e., within 3 years) of any clinically significant neurological,
             gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, endocrine,
             hematological, dermatological, psychological, ophthalmological, allergic or other
             major disorders;

          -  Use of any prescribed systemic or topical medication within 30 days of the first
             dose;

          -  Use of any non-prescribed systemic or topical medication (including vitamin/mineral
             supplements and herbal medicines, e.g., St. John's Wort) within 7 days of the first
             dose administration;

          -  Exposure to an investigational drug (new chemical entity) within 30 days prior to the
             first dose administration
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Palmisano, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 5, 2012</lastchanged_date>
  <firstreceived_date>September 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AVL-292</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Pharmacology, Clinical</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
